Research programme: therapeutic agents - Pharmacopeia/Schering-Plough

Drug Profile

Research programme: therapeutic agents - Pharmacopeia/Schering-Plough

Alternative Names: PS 015146; PS 241541

Latest Information Update: 11 Feb 2009

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Pharmacopeia; Schering-Plough
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Cancer; Inflammation; Metabolic disorders; Respiratory tract disorders; Unspecified

Most Recent Events

  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
  • 19 Apr 2007 Another candidate has been selected by Schering-Plough for preclinical development
  • 17 Apr 2007 Preclinical trials in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top